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Abstract
Stabilised peptides are now established as potential drug candidates to probe previ-
ously intractable molecular targets, such as protein-protein interactions. Herein, we
report the design and synthesis of eight short helical peptide analogues of the ubiquitin
conjugating enzyme, E2-25K, as potential antagonists of the interaction between
E2-25K and the Alzheimer's Disease (AD) associated ubiquitin mutant Ubb + 1. Bio-
chemical evaluation revealed four putative antagonists of the Ubb + 1/E2-25K interac-
tion that reduced incorporation of Ubb + 1 into polyubiquitin chains in vitro, validating
the potential of this approach as a therapeutic strategy.
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1 | INTRODUCTION
In Alzheimer's disease (AD) there is an urgent need for understanding
disease pathomechanisms that underlie the accumulation of neuro-
toxic protein aggregates which represent the characteristic pathologi-
cal hallmarks of the condition.[1] Improved knowledge of protein
interactomes, and the physiological significance of post translational
modifications has led scientists to probe the link between malfunction
of important cellular regulatory processes and the onset of neu-
rodegeneration.[2,3] Of particular interest is protein ubiquitination as
part of the ubiquitin proteasome system (UPS) which mediates degra-
dation of intracellular proteins in a non-lysosomal approach.[4] Within
the UPS, excess or misfolded proteins are covalently tagged with
polyubiquitin chains through a multiple enzyme ligation process.
Ubiquitin (Ub) is conjugated to the E1-activating enzyme through an
ATP-mediated thiol bond between the C-terminal Gly of Ub and a Cys
of E1. The activated Ub is then transferred to an E2-conjugating
enzyme through transacylation to another Cys site on the E2. The
E2-Ub complex then interacts with an E3 ligating enzyme bound with
the protein marked for degradation by the UPS, transferring the Ub to
a Lys residue of the target. The conjugated Ub can itself be
ubiquitinated through one of its lysine residues, commonly through
Lys48 for a UPS signal, giving rise to polyubiquitin chains which chap-
erone the target protein into the proteasome for degradation.
It has been shown that function of the UPS could be inhibited in
AD, however the mechanism(s) by which this important regulatory
system is malfunctioning is incompletely understood. One such mech-
anism is mediated through a frameshift mutant form of ubiquitin,
Ubb + 1, which has been shown to accumulate in the neurons of
patients with AD,[5–8] but is absent in age matched non-disease
controls.
Ubb + 1 has an primary amino acid related sequence to Ub, how-
ever, contains a C-terminal 19 amino acid extension, lacking the free
Gly76 essential for conjugating to UPS targets. in vitro and in cellulo
studies in our own laboratories have shown Ubb + 1 can itself be
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ubiquitinated, creating Ubb + 1 capped polyubiquitin chains.[9] These
chains have shown resistance to de-ubiquitinating enzymes, and are
capable of binding to and completely inhibiting the proteasome. Fol-
lowing on from this initial data, a review of subsequent literature sug-
gests that this original hypothesis is broadly supported, and offers
further insight into the age-dependent accumulation of Ubb + 1, and
how Ubb + 1-mediated proteasome inhibition may contribute to
Alzheimer's disease.[10]
Incorporation of Ubb + 1 into the unanchored polyubiquitin
chains is mediated through the protein-protein interaction (PPI)
between Ubb + 1 and the conjugating enzyme E2-25K through a Ub-
binding associated domain (UBA, Figure 1).[11,12] This relatively small
400 Å2 PPI could provide a novel target for AD therapeutics as it is
critical for the incorporation of Ubb + 1 into polyubiquitin chains. The
Ub-binding domain of E2-25K is dominated by a short α-helical motif
(labelled α-9), which binds to Ubb + 1 through predominantly hydro-
phobic interactions of Val120, Thr124 and Leu128 with the Ubb + 1 sur-
face, and a single salt-bridge between Glu125 and Arg42 of E2-25K
and Ubb + 1, respectively (Figure 2).
PPIs as potential drug targets have historically been difficult to
target due to their large surface area which is generally devoid of
pocket-like structures in which small molecules can bind.[13] Despite
recent advances in identifying “hot-spots” that might serve as bind-
ing sites for small molecule inhibitors, using macromolecular con-
structs has proven effective in targeting various PPIs, and in
particular short peptide mimics of the parent protein.[14] Pioneering
work by both Grubbs and Verdine have shown that it is possible to
inhibit PPIs through creating stabilised helical peptides capable of
mimicking the α-helical interface at the PPI surface.[15–18] The use
of stabilised peptides allows for maximum specific interactions with
the target surface in the absence of any small molecule binding sites
through combining the non-covalent forces and topological recogni-
tion of the parent sequence. Based on this strong precedence, we
elected to employ the technique of peptide stapling for our initial
studies into inhibiting the E2-25K/Ubb + 1 PPI by creating a
focused palette of short helical peptide analogues of the α-9 helix
of E2-25K.
2 | MATERIALS AND METHODS
2.1 | General
All reagents, resins and solvents were obtained from commercial sup-
pliers and were used without further purification unless otherwise
stated. Purified solvents were stored in a septum-sealed oven died
flask over previously activated 4 Å molecular sieves, and purged and
stored under N2. Anhydrous THF and DCM were obtained from a
PureSolv SPS-400-5 solvent purification system.[19]
2.2 | Solid phase peptide synthesis
Reagents used in SPPS were as follows: All Fmoc-protected amino acids
were purchased from Novabiochem unless stated in the text. Rink amide
MBHA resin (0.78 mmol/g loading) was purchased from Novabiochem.
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium
3-oxide hexafluorophosphate (HATU) and 1-Hydroxy-7-azabenzotriazole
(HOAt) were purchased from Fluorochem. Triisopropyl silane (TIS), Piper-
idine, N-methylmorpholine (NMM) and Trifluoroacetic acid (TFA) were
purchased from Alfa Aesar. Acetic anhydride, Diisopropylethylamine
(DIPEA) and Bis(tricyclohexylphosphine)benzylidine ruthenium(IV)
dichloride (Grubbs first generation catalyst) were purchased from Sigma-
Aldrich. All solvents were purchased from Sigma-Aldrich with the excep-
tion of dimethylformamide (DMF) which was purchased from Rathburn
Chemicals Ltd.
All automated couplings were carried out on a Protein Technolo-
gies, Tribute automated synthesizer.
Resin was swollen in DCM for 10 min prior to any synthesis.
Deprotections were carried out using a solution of 20% piperidine in
DMF (3 × 5 min). N-terminal capping was achieved using 15% acetic
anhydride in DMF (3 × 5 min). All standard couplings were carried out
using HATU (5 equiv.), amino acid (5 equiv.) and DIPEA (10 equiv.) in
DMF. Alkene containing amino acid couplings were carried out using
a Merrifield bubbler with HATU (2.5 equiv.), amino acid (2.5 equiv.)
and DIPEA (5 equiv.) in DMF. N-terminal threonine couplings were
F IGURE 1 The Ubb + 1/E2-25K proteinprotein interaction. Main interaction surface between Ubb + 1 and E2-25K coloured by domain of
E2-25K. α-9 (dark purple) within the ubiquitin binding domain (UBA) dominates the PPI with some additional interactions from the loop between
α-8 and α-7 of E2-25K. Crystal Structure PDB ID: 3K90
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carried out using HATU (5 equiv.), HOAt (4 equiv.), amino acid
(5 equiv.) and DIPEA (10 equiv.) in DMF. Coupling times varied per
peptide as presented in the Supporting Information.
Ring-closing metathesis was achieved using 40 mol% Grubbs first
generation catalyst in DCM (10 mM). Methathesis was complete after
3 × 2 Hr reactions under sonication.
For the synthesis of staple 8, FmocGlu(OAllyl)OH was employed.
Allyl deprotection was carried out using 4 × Pd(PPh3)4 (10 mol%) and
PhSiH3 (10 equiv.) in DCM followed by 4 × Sodium diethyldi-
thiocarbamate trihydrate (0.8 equiv) in DMF. This was followed by
HATU-mediated cyclisation to furnish the pyroglutamate analogue.
All peptides were cleaved using a mixture of TFA/TIS/H2O
(95:2.5:2.5) for 4 h, filtered and precipitated into Et2O. Centrifugation
and preparative HPLC gave the completed peptides. Reverse-phase
HPLC purification of peptides was carried out using a Gilson prepara-
tive HPLC system of 322 pumps coupled to a 151 UV/Vis spectrome-
ter, 234 Autoinjector and a GX-271 liquid handler using a Agilent
Zorbax SB-C18, 21.2 × 100 mm, 5 μ column at room temperature.
Purifications were performed using gradient methods ranging from
5% to 90% MeCN in H2O over 30 min at a flow rate of 10 mL/min.
Analysis was carried out using Gilson Trilution software.
Reverse-phase analytical HPLC analysis of peptides was carried
out on an Agilent 1260 Infinity system using a Macherey Nagel, EC
250/4.6, Nucleodur C18 Gravity, 5 μm Column at room temperature.
Purity was required to be ≥90% by UV at 214 nm over a gradient of
5%-95% MeCN in H2O for 30 min.
2.3 | Circular dichroism spectroscopy
Circular Dichroism was carried out on an Applied Photophysics
Chirascan plus CD spectrometer with temperature control. All sam-
ples were prepared using phosphate buffer solution (50 mM, pH 7).
For 0.1 and 1 mm cells, peptides were made to a concentration of
200 and 50 μM, respectively. Machine parameters for each sample
were as follows: Wavelength = 190-260 nm, Step resolution = 0.5 nm,
accumulations = 10, Bandwidth = 1 nm, Temperature = 20 C. All
spectra were measured in ellipticity (mdeg) after background sub-
straction. All curves shown are smoothed using standard parame-
ters. Helicity calculated from mean residue ellipticity (Equation 1)
divided by maximum mean residue ellipticity (Table 1) at 222 nm
where T = Temp (C) = 20 C, n = no. of amino acids in peptide = 11,
K = Correction factor = 3, C = Sample concentration (M), l = Cell
path length (mm).
%helicity = [θ]222/[θ]max (1)
where
θ½ 222 = θobs Clnð Þ; θ½ max = −44000+250Tð Þ 1−
K
n
 
2.4 | Peptide NMR
1H, NOESY and TOCSY data were obtained at 600 MHz using
aBruker Advance II+ NMR with Staple 1 diluted to 2 mM in phosphate
buffer (50 mM, pH 7, 10% D2O, 90% H2O) and COSY data was
obtained with Staple 1 diluted to 2 mM in D2O. One-dimensional 1H
NMR data were acquired using a Bruker excitation sculpting sequence
(zgesgp) to eliminate the solvent resonance. Data was acquired at
128 scans over a frequency of 7.2 kHz (12 ppm), centred at
4.703 ppm into 32.8 K data points (acquisition time of 2.27 s) with a
total spectra time of 9 min. SPARKY NMR visualisation software was
used to interpret, assign and integrate all 2D spectra.[20]
2.5 | In vitro polyubiquitination assays
10× Reaction buffer stock solution contained 500 mM Tris buffer,
100 mM MgCl2, 10 mM ATP, 10 mM DTT (pH 7.5). Peptides were
prepared as a 300 μM stock solution in reaction buffer.
All reaction were carried out containing Ubb + 1 (50 μM), Ub
(50 μM), E1 (0.1 μM), E2-25K (1 μM) and test peptide (30 μM) and
made up to 50 μL with distilled water.
F IGURE 2 Key interactions between
Ubb + 1 (Blue) and E2-25K (Purple).
Lipophilicity of Ubb + 1demonstrated,
with hydrophilic sections shown in dark
blue, and lipophilic surfaces shown in lime
green. The α-9 helix of E2-25K is shown
in purple with key residues and their
interactions highlighted. The Ubb + 1/
E2-25K PPI is dominated by hydrophobic
interactions and a key salt bridge between
Glu125 of E2-25K with Arg42 of Ubb + 1
TABLE 1 calculated maximum mean residue ellipticity at 222 nm
Temp. (C) n [θ]max
20 11 −28 364
20 12 −29 250
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The reactions were incubated for 4 h at 37 C on a shaking incu-
bator then quenched with 20 μL of SDS-PAGE gel application buffer.
The reaction solution was then split into equal 35 μL aliquots and run
on a 5%-20% SDS-PAGE gradient gel. Following western transfer to
nitrocellulose, one set of samples was probed vs anti-VU1 (anti-
ubiquitin, 1:1000) and the other vs anti-Ubb + 1 (1:1000).
2.6 | Molecular modelling
Chemical Computing Group's Molecular Operating Environment
(MOE) software was used to visualize, edit and compute all structures.
An AMBER12:EHT force field was used for all structures.[21] Peptide
models were created through modifications of the crystal structure of
E2-25K in complex with Ubb + 1 (PDB ID 3K9O).[11] The structure of
E2-25K was edited to only the α9 segment (Val190 − Asn200) and
modified to each peptide structure using the “builder” function of the
software. All i, i + 4 staples were assumed to be cis configuration and
all i, i + 7 staples were assumed to be trans based on the study by
Verdine et al.[17] Free peptides were energy minimised, then
minimised again against the full Ubb + 1 structure.
3 | RESULTS AND DISCUSSION
As stated above, the current study centred around the synthesis of a
focused array of stapled peptides as small helical surrogates of
E2-25K. In the first instance, a control peptide which contained the
11 amino acid sequence of α-9 from wild type E2-25K with no struc-
tural constraint was prepared. A range of i, i + 4 staples were designed
based on this sequence which were anticipated not to disrupt the key
hydrophobic and electrostatic interactions crucial for binding with the
surface of Ubb + 1 from consideration of the available crystal struc-
ture of the complex and associated NMR data.[11] Peptide staples 1, 2,
3 and 6 contain the all hydrocarbon linker at differing points in the
sequence, resulting the staple itself being exposed to solvent (con-
structs 1 and 3) or potentially against the Ubb + 1 surface (peptides 2,
and 6). Peptide staple 5 was examined to confirm the previous
F IGURE 3 Proposed stapled peptide analogues of α-9 of E2-25K. (A) - The α-9 helix of E2-25K consists of an 11 amino acid sequence.
Residues shaded are essential for target binding with Ubb + 1. (B) Short helical peptide derived from the sequence of E2-25K were designed.
Variation in staple position and length could give significant differences in peptide helicity or target affinity. (C) Model of staple 1 binding with
Ubb + 1. Residues highlighted in blue correspond to those highlighted in the sequence of E2-25K deemed essential for binding with Ubb + 1
F IGURE 4 Circular Dichroism spectra of designed stapled
peptides. The wild type sequence, shown in black, has no protein
secondary structure exhibiting an unstructured CD spectra with a
single minima at 200 nm. All other peptides exhibited a helical
secondary structure, with maxima at 198 nm and minima at 208 and
222 nm. Helicity was calculated from the mean residue ellipticity at
222 nm and maximum mean residue helicity for the sequence
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literature precedent that (R), (R) i, i + 4 staples are in general less heli-
cal in nature than their corresponding (S), (S) counterparts.[22] An i, i
+ 7 staple was also designed with the hydrocarbon linker towards the
C-terminal end of the peptide sequence (construct 4; Figure 3).
An isomeric peptide system, staple 7, was designed in which the
primary amino acid sequence of staple 1 was reorganised to deter-
mine if replacements at certain positions in the sequence could be tol-
erated whilst maintaining the physicochemical properties of the
peptide compared to staple 1. In particular, we were interested
whether Glu[6] could be substituted to a Thr and still maintain a key
hydrogen-bond with Arg42 of Ubb + 1. Finally, an N-terminal cyclised
analogue of staple 1 was designed (construct 8) in which Glu[10]
would be selectively deprotected on the solid phase, then cyclised
onto the backbone NH of Val[11] using standard HATU chemistry (see
Supporting Information for further details). It was proposed that this
N-terminal cyclisation would facilitate further hydrophobic interac-
tions with the surface of Ubb + 1 as the side chain acid of Glu[10] has
no key interactions with Ubb + 1 from consideration of the available
X-ray data.
Peptides were synthesised using standard SPPS procedures
adapted for hydrocarbon stapling methodology, as detailed in the
materials and methods section. A total of nine peptides were
synthesised in >90% purity by HPLC, including the wild type
sequence of α-9 of E2-25K, and eight stapled analogues.
Following assembly by SPPS, the completed peptides were ana-
lyzed by CD spectrometry in order to determine the helical content of
each staple compared to the unstabilised wild type peptide. As
expected, the unstapled wild type sequence was unstructured, how-
ever all stapled analogues showed helical structures in phosphate
buffer with maxima at 195 nm and dual minima at 208 and 222 nm
(Figure 4). Staple 1 was shown to be remarkably ordered in solution,
with a calculated helicity of 91%.
Construct 5, in which the stereochemistry of the staple is inverted
compared to that of staple 1, had markedly reduced helical character
(16%) which was consistent with the earlier literature findings that
(R)/(R) i, i + 4 staples are in general less ordered that the (S)/(S) sta-
ples.[22] The N-terminal cyclised analogue of Staple 1, Staple 8 also
had a reduced helicity of 39%, however this value was more
F IGURE 5 1H NOESY data of staple 1. (A) Cα-NH region from the NOESY spectrum of staple 1 with two ring-closed S5 residues defined as
4* and 8*. Black lines indicate interactions between backbone amide protons and the alpha proton of the same residue (E10Ha - NH), or between
a backbone NH and the alpha proton of the next residue in the sequence (V11Ha - E10NH). Longer range interactions are only possible from a
coiled helical structure and indicated by yellow circles. (B) Amide NH-NH region from the NOESY spectrum of staple 1. Black lines indicate the
walk along the backbone sequence (V11HN - E10HN). (C) Graphical representation of through space interactions indicating helical nature of the
system
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consistent with the other i, i + 4 systems 2, 3 and 6 which had helicity
values of 41%, 42% and 42%, respectively. The i, i + 7 staple exam-
ined, staple 4, also had a very high helicity value of 80%. Lastly the
isomeric helix analogue, staple 7, had a much reduced helicity value of
only 24%, indicating that amino acid sequence has a large effect on
the secondary structure of these short peptides despite the all-
hydrocarbon staple bridge being present.
The elevated levels of helicity exhibited by staple 1 are some-
what rare for stapled peptides, therefore a more complete struc-
tural analysis of this peptide was carried out by NMR in order to
confirm the structure. 1H, NOESY and TOCSY spectra were
acquired in phosphate buffer 90% H2O: 10% D2O, and COSY in
100% D2O allowing for complete assignment of all the residues of
staple 1.
Analysis of the NOESY spectra indicated that an α-helical struc-
ture was clearly present (Figure 5). Due to the spiral configuration of
an α-helix, the NH and αH backbone protons all point parallel to one
another which allows for characteristic NOE patterns. The amide NH
protons all orientate towards the N-termini along with all S-amino acid
side chains, while all the αH protons point towards the C-termini. Due
to this conformation, an NOE walk along the backbone can be noted
for each sequential NH-NH and NH-αH interaction at the i, and i + 1
positions. In the case of staple 1, the majority of the NH protons in
the 11 amino acid sequence experienced an NOE from the preceding
F IGURE 6 Temperature
ramped CD spectra of Staple 1
F IGURE 7 E2-25K-mediated polyubiquitin chain formation. The E2-25K conjugating enzyme (green) has two distinct binding domains. During
the ubiquitination cascade, an E1 enzyme (yellow) brings a ubiquitin moiety (purple) towards the E2 binding domain of E2-25K. This Ub could
itself be polyubiquitinated, provided the C-terminus is free for conjugation. An isopeptide bond is formed between the C-terminal Gly76 of Ub and
the Cys96 of E2-25K. Ubb + 1 (red) can then bind to the UBA specific domain of E2-25K, bringing it into proximity of ubiquitin (or the growing
polyubiquitin chain). A new covalent bond is formed between Lys48 of Ubb + 1 and Gly76 of Ub giving a Ubb + 1 capped polyubiquitin chain
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residue Similarly, all α-protons also experienced an NOE from the pre-
ceding backbone NH proton, with the exception being the S5 residues
which lack an α-proton. This is strong evidence of an α-helical second-
ary structure as such NOE interactions would not be observed in an
unstructured peptide. Full NOE data is presented in the Supporting
Information.
In addition to the NMR studies of Staple 1, it was also of interest
to study the thermal stability of the constrained α-helix. This was
accomplished using CD spectroscopy due to the relative ease of tem-
perature ramping peptides in solution as well as the clear indication of
helical content. In these studies it was shown that Staple 1 had signifi-
cant tolerance for temperature, with helicity being maintained up to
80 C in phosphate buffer (Figure 6). It was interesting to note that
the percent helicity of Staple 1 decreased on average by 2% per 5 C
increase in temperature. At the maximum temperature tested, Staple
1 maintained a 68% helical structure. It was also noteworthy that
upon cooling back to 20 C, the peptide regained its highly ordered
structure with the helicity returning to the original value of 89%.
Following synthesis and structural determination, the target pep-
tides were then subjected to biological evaluation. An in vitro poly-
ubiquitination assay was employed to probe the efficacy of our
E2-25K peptide analogues in antagonizing the interaction between
E2-25K and Ubb + 1. During E2-25K-mediated polyubiquitination,
ATP facilitated ligation of Ub to an E1 enzyme via Gly76 begins the
polyubiquitination cascade. As shown in Figure 7, the single ubiquitin,
or pre-formed polyubiquitin chain, is then transferred to Cys98 of con-
jugating enzyme E2-25K.
The precise mechanism by which E2-25K-mediated poly-
ubiquitination occurs is not fully defined, however it can be assumed that
at this point in the polyubiquitination process, a Ub, or Ubb + 1 moiety
can then non-covalently bind to the UBA domain of E2-25K.[11,12,23] At
this point, the covalent link between Lys48 of Ubb + 1 and Gly76 of Ub
F IGURE 8 Western blot analysis of
polyubiquitination assays. (A) Western
blot of polyubiquitin chains. No change
for any peptides against the control
indirectly indicates that peptides do not
bind to Ub with appreciable affintiy.
(B) Western blot of Ubb + 1 capped
polyubiquitin chains. Line highlighted in
red shows Ubb + 1-Ub3 chains. + and −
indicate presence and absence of ATP
(required for Ub conjugation activity, −
representing control)
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must be formed, giving a Ubb + 1 capped polyubiquitin chain (Figure 7).
As noted previously, once formed in vivo, these toxic Ubb + 1 capped
polyubiquitin chains can impair proteasomal function which is potentially
a feature of early stage AD.
As discussed previously, it was anticipated that these small peptide
mimics of E2-25K would be capable of selectively binding with Ubb + 1.
This would theoretically block any further interaction of Ubb + 1 with
E2-25K, preventing incorporation of Ubb + 1 into polyubiquitin chains. It
was reasoned that any interaction between our peptides and Ubb + 1
was likely to be weak in nature as the parent PPI between Ubb + 1 and
E2-25K is also reasonably weak (Kd = 0.939 ± 0.218 mM).
[11] Previous
study by Eom and Lee et al. has shown that deletion constructs of
E2-25K which lack the UBA domain are capable of forming short Ubb + 1
capped polyubiquitin chains (Ub n = 1) suggesting the UBA domain is
merely a directing group for E2-25K action, especially in facilitating longer
Ubb + 1 capped polyubiquitin chains.
The polyubiquitination assay was run in duplicate for 4 h con-
taining target peptides, E2-25K, Ub, Ubb + 1, E1 and ATP, with test
peptides evaluated at 30 μM concentrations.
Analysis of the assay results from western blot analysis (Figure 8)
revealed that a number of the target peptides had some efficacy in
inhibiting the synthesis of longer Ubb + 1 capped polyubiquitin chains
(Ub n ≥ 3) with little effect on the synthesis regular polyubiquitin
chains included as a negative control. As shown above, staples 6 and
7 blocked formation of the higher order Ubb + 1-Ub3 polyubiquitin
chains (red box, B), whilst staples 2 and 8 had similar but more limited
effects compared to controls. This readout indicated that these four
peptides appeared to be selective antagonists for Ubb + 1 over Ub,
blocking the longer Ubb + 1 capped polyubiquitin chains, which are
generally inhibitors of the proteasome.[5,10,11,24] This apparent selec-
tivity could be rationalised by the conformational differences between
the Ub/E2-25K interaction compared to the Ubb + 1/E2-25K PPI.
F IGURE 9 Models of active peptides binding with Ubb + 1. (A) Energy minimised structure of staple 8 with Ubb + 1; (B) Energy minimised
structure of staple 10 with Ubb + 1; (C) Energy minimised structure of staple 2 with Ubb + 1 and (D) Energy minimised structure of staple 11 with
Ubb + 1. All models created using PDB ID:3 K90
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The crystal structures solved by Eom and Lee et al. suggested a con-
formational tilt of 15 between Ubb + 1 with E2-25K compared to
Ub, allowing for closer hydrophobic interactions with the α-9 helix of
E2-25K.
A computational investigation into the possible binding modes of
these peptides was then used in an effort to discern a structure activ-
ity relationship for the series. Models of the most active peptides
were created from the known crystal structure of the Ubb + 1/
E2-25K PPI.[11]
For the peptides associated with biological activity, molecular
modelling (Figure 9) shows that the key hydrogen bond essential for
binding between the peptides and Arg42 of Ubb + 1 is maintained. In
the case of staple 7, the substitution of Glu for Thr does not appear to
disrupt this interaction. For staples 6 and 2, the hydrocarbon linker
appears to interact with the hydrophobic surface of Ubb + 1. This
could prove to be essential for the observed activity, as other staples
(1, 2, 4 and 5) in which the linker is proposed to be solvent exposed
rather than against the Ubb + 1 surface are inactive despite
maintaining many other binding characteristics. The activity of staple
8 appears to be driven by similar hydrophobic interactions as the N-
terminal cyclisation is conferring a conformational change, allowing
for closer interactions with the surface of Ubb + 1, unlike the
uncyclised analogue staple 1. It was interesting to note that staple
7 appeared to be active against Ubb + 1, despite having an isomeric
sequence compared to the native E2-25K. However, from consider-
ation of the modelling data, it would appear that the C-terminal Glu of
staple 8 is capable of forming a hydrogen bond with the backbone NH
of Lys48 of Ubb + 1. This could potentially occlude the key site for
polyubiquitination, as Lys48 forms the isopeptide link with Gly76 of
the growing polyubiquitin chain, hence potentially accounting for the
observed biological activity.
These results are particularly interesting in that the extent of
helicity of the peptide analogues of E2-25K does not appear to be a
factor in determining binding affinity with Ubb + 1 as the most helical
analogues, staples 1 and 4 were apparently inactive. By contrast, bind-
ing with Ubb + 1 appears to be driven by strong hydrophobic interac-
tions, with the staple component itself potentially being beneficial
with binding to our target.
4 | CONCLUSIONS
This work has demonstrated the feasibility of generating antagonists
of the Ubb + 1/E2-25K interaction using peptide stapling methodol-
ogy. A palette of peptides were successfully synthesised based on the
α-9 sequence of E2-25K including the wild type sequence and eight
stapled analogues with varying helicity values of 16%-91%. The
exceptional level of helicity observed in staple 1 (91% in phosphate
buffer) was further confirmed by NMR studies.
Four i, i + 4 stapled peptides showed varying activity against the
formation of chain Ubb + 1 capped polyubiquitin chains in vitro. These
peptides were remarkably also selective for Ubb + 1 against Ub, which
could be accounted for by differences in binding modes between the
two proteins. Modelling derived from the X-ray crystal structure of
E2-25K in complex with Ubb + 1 was used in conjunction with bio-
logical data to offer some insight into the activities observed which
is likely driven by hydrophobic interactions. Of particular interest
was the interplay between the peptide helicity, staple position and
target affinity with Ubb + 1 as the most structurally well-defined
sequence (staple 1) was inactive in our assay, whilst more flexible
sequences in which the staple itself could participate in hydrophobic
interactions with the binding surface were favoured. Overall, this
study has shown that stapled helical analogues of the α-9 segment
of E2-25K can selectively inhibit the formation of long chain Ubb
+ 1 capped polyubiquitin chains whilst maintaining regular poly-
ubiquitination, at least in vitro. These tool compounds will be of fur-
ther use in exploring the role of Ubb + 1 in proteasomal inhibition.
Further studies in our laboratories will focus on biophysical charac-
terisation of the interactions between this emerging class of stapled
peptides and UBB + 1 (including thermal melting and ITC measure-
ment), the design of related peptides based on biostructural consid-
erations to improve the observed activity, and confirmation of
activity in a cell-based preparation.
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